Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunoproliferative small intestinal disease: current concepts.

Philip A Salem1, Fadi F Estephan

  • 1St. Luke's Episcopal Hospital and the University of Texas Medical School, Houston, Texas, USA. salem@pasalem.com

Cancer Journal (Sudbury, Mass.)
|November 2, 2005
PubMed
Summary

Immunoproliferative small intestinal disease (IPSID) is a unique disorder with an early, potentially benign phase. Antibiotic treatment in this phase may lead to remission, suggesting chemoprevention possibilities for lymphomas.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Can Significant Coronary Artery Disease Coexist With Transient Takotsubo Cardiomyopathy, and How Does Spasm Interrelate?

Texas Heart Institute journal·2023
Same author

Novel MicroRNAs regulating proliferation and apoptosis in uterine papillary serous carcinomas.

Cancer letters·2013
Same author

Michael E. BeBakey, M.D.: the real man behind the genius.

Methodist DeBakey cardiovascular journal·2010
Same author

Complete remission with anti-CD20 therapy for unicentric, non-HIV-associated, hyaline-vascular type, Castleman's disease.

Cancer investigation·2005
Same author

Epiphora induced by intermittent docetaxel (taxotere) in patients with non-small cell lung cancer.

Cancer investigation·2003

Area of Science:

  • Gastroenterology
  • Oncology
  • Immunology

Background:

  • Immunoproliferative small intestinal disease (IPSID) is a distinct lymphoproliferative disorder characterized by a specific abnormal protein.
  • IPSID presents a unique early phase with benign-appearing histology, the malignant potential of which remains unknown.
  • Unlike focal lymphomas, IPSID exhibits diffuse mucosal infiltration, leading to malabsorption.

Purpose of the Study:

  • To investigate the characteristics of immunoproliferative small intestinal disease (IPSID).
  • To explore the potential for remission and chemoprevention in the early stages of IPSID.
  • To understand the pathogenesis and epidemiological trends of IPSID.

Main Methods:

  • Review of clinical and pathological features of IPSID.

Related Experiment Videos

  • Analysis of treatment outcomes, including antibiotic therapy in the early phase.
  • Examination of epidemiological data and suspected environmental factors.

    • Main Results:

    • IPSID is the only lymphoproliferative disorder with a specific abnormal protein and a potentially benign early phase.
    • Antibiotic treatment of the early phase has resulted in remission in some patients.
    • Epidemiological data suggest a decrease in IPSID incidence in endemic areas, implicating environmental factors.

    Conclusions:

    • The early phase of IPSID may be amenable to antibiotic treatment, raising questions about lymphoma chemoprevention.
    • Environmental factors likely play a significant role in IPSID pathogenesis.
    • Further research is crucial for understanding IPSID and lymphomas in general.